Company
Emyria Limited
Headquarters: West Leederville, WA, Australia
Market Cap
A$20.2 Million
AUD as of Jan. 1, 2024
US$13.7 Million
Emyria Limited Categories
Australia Healthcare Health Information ServicesAustralia Healthcare Australia Health Information Services
Top Competitors by Market Capitalization
Industry: Health Information Services
| Company | Market Cap (USD) |
|---|---|
| GE HealthCare | $34.86 B |
| Veeva Systems Inc. | $29.97 B |
| M3, Inc. | $11.24 B |
| Change Healthcare Inc. | $9.03 B |
| Signify Health, Inc. | $8.38 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Emyria Limited, a clinical drug development and care delivery company, operates a network of specialist medical clinics. Its product pipeline include EMD-003, a cannabinoid medicine for treating patients with mental health; and EMD-004, a cannabinoid medicine targeting irritable bowel syndrome. The company also provides a data platform that manages, monitors, and improves the safety and efficacy of novel treatments for patients with unmet medical needs. In addition, its medical clinics offer treatments, such as cannabinoid-based medicines. The company has a partnership agreement with Mind Medicine Australia to develop a national care program and data registry for psychedelic-assisted therapies. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Emyria Limited has the following listings and related stock indices.
Stock: ASX: EMD wb_incandescent